Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 15/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965184 | 0.84 | NPSR1 (0.44) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL161668 | 0.81 | RAF1 (0.56) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1912421 | 0.79 | RAF1 (0.51) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL173108 | 0.79 | RAF1 (0.56) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10264809 | 0.79 | L3MBTL1 (0.53) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14467713 | 0.78 | RAF1 (0.60) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL28291594 | 0.77 | MAPT (0.44) | RAF1MAPTPKM | |
| SCHEMBL13425471 | 0.76 | RAF1 (0.65) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3219082 | 0.76 | RAF1 (0.48) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL161941 | 0.76 | L3MBTL1 (0.60) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20110178058-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178129-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011088345-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES , INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2011011303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | RAF1 1470/4885MAPK14 2109/4885MAPK13 2214/4885 |
| US-20110178058-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | RAF1 1470/4885MAPK14 2109/4885MAPK13 2214/4885 |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | RAF1 1470/4885MAPK14 2109/4885MAPK13 2214/4885 |
| US-20110178129-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | RAF1 1470/4885MAPK14 2109/4885MAPK13 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.